TrialClinical pharmacokinetics2019

Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.

Carlos Fernandez-Teruel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.